Ovarian Cancer

Oncology
102
Pipeline Programs
30
Companies
50
Clinical Trials
8 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
25
13
53
2
8
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1452%
Small Molecule
933%
Cell Therapy
27%
ADC
27%
+ 92 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
CARBOPLATINApproved
carboplatin
Unknown Company
intravenous2005

Competitive Landscape

61 companies ranked by most advanced pipeline stage

Genentech
6 programs
5
1
CarboplatinPhase 31 trial
BevacizumabPhase 2Monoclonal Antibody1 trial
BevacizumabPhase 2Monoclonal Antibody
DNIB0600APhase 21 trial
DoxilPhase 2
+1 more programs
Active Trials
NCT00408070Terminated5Est. Oct 2009
NCT01991210Terminated95Est. Aug 2016
NCT00866723Terminated5Est. Jun 2012
+1 more trials
Zai Lab
4 programs
1
2
1
ZL-2306Phase 31 trial
NiraparibPhase 21 trial
ZL-2306Phase 21 trial
ZL-2306Phase 11 trial
Active Trials
NCT03551171Completed42Est. Jul 2018
NCT04217798Unknown36Est. Jun 2022
NCT04392102Completed15Est. Aug 2022
+1 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
3 programs
1
1
1
Mirvetuximab soravtansine plus BevacizumabPhase 3ADC1 trial
ABT-888Phase 21 trial
ABBV-901Phase 11 trial
Active Trials
NCT07278336Recruiting207Est. Jan 2029
NCT00526617Completed41
NCT05445778Recruiting520Est. May 2032
Chipscreen Biosciences
3 programs
1
1
1
chiauranibPhase 3Small Molecule1 trial
chiauranibPhase 2Small Molecule1 trial
ChiauranibPhase 1/2Small Molecule1 trial
Active Trials
NCT03166891CompletedEst. Mar 2019
NCT03901118CompletedEst. Dec 2020
NCT04921527RecruitingEst. Jul 2025
E
3 programs
2
1
FarletuzumabPhase 3Monoclonal Antibody1 trial
LenvatinibPhase 1/2Small Molecule1 trial
decitabinePhase 1/21 trial
Active Trials
NCT01133756Terminated7Est. Sep 2012
NCT00477386Completed28Est. Sep 2013
NCT00849667Terminated1,100Est. Apr 2013
Roche
3 programs
1
2
PaclitaxelPhase 35 trials
atezolizumab + avastin + platinum-based chemotherapyPhase 31 trial
pertuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT02004093Completed149Est. Sep 2008
NCT05775289Active Not Recruiting182Est. Jun 2026
NCT03038100Completed1,301Est. Aug 2022
+4 more trials
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
Pamiparib capsulePhase 31 trial
Active Trials
NCT03519230Active Not RecruitingEst. Jan 2027
Sutro Biopharma
Sutro BiopharmaSOUTH SAN FRANCISCO, CA
3 programs
2
1
Luveltamab tazevibulinPhase 2/31 trial
STRO-002Phase 11 trial
STRO-002Phase 11 trial
Active Trials
NCT05200364Terminated58Est. Jun 2025
NCT03748186Completed136Est. Jun 2024
NCT05870748Terminated600Est. Aug 2025
AS
1 program
1
MasitinibPhase 2/3Small Molecule1 trial
Active Trials
NCT02490488CompletedEst. Dec 2020
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
8 programs
2
OlaparibPhase 21 trial
OlaparibPhase 21 trial
A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients N/A1 trial
Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCAN/A1 trial
China Ovarian Cancer BRCA Testing StudyN/A1 trial
+3 more programs
Active Trials
NCT05918042Active Not Recruiting400Est. Jul 2025
NCT03229122Completed446Est. Jul 2018
NCT03203993Terminated29Est. Mar 2020
+5 more trials
M&
6 programs
5
CarboplatinPhase 25 trials
OlaparibPhase 21 trial
PembrolizumabPhase 2Monoclonal Antibody1 trial
PembrolizumabPhase 2Monoclonal Antibody1 trial
TuvusertibPhase 2Small Molecule1 trial
+1 more programs
Active Trials
NCT06036810Recruiting70Est. Oct 2027
NCT06719973WithdrawnEst. May 2025
NCT05952453Recruiting20Est. Dec 2030
+7 more trials
Alliance Pharmaceuticals
5 programs
2
1
DoxilPhase 21 trial
MOv19-BBz CAR T cellsPhase 1Cell Therapy1 trial
Topotecan and VP16Phase 11 trial
KetorolacN/A1 trial
Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based StudyN/A1 trial
Active Trials
NCT02470299Completed21Est. Jan 2024
NCT00323726Withdrawn0Est. Dec 2006
NCT03585764Terminated46Est. Mar 2024
+2 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
4 programs
4
BevacizumabPhase 2Monoclonal Antibody1 trial
LY2523355Phase 21 trial
PrexasertibPhase 2Small Molecule1 trial
gemcitabinePhase 21 trial
Active Trials
NCT00267696Completed45Est. Dec 2013
NCT01059643Completed103Est. Dec 2012
NCT03414047Completed172Est. Oct 2020
+1 more trials
Takeda
TakedaTOKYO, Japan
3 programs
1
1
PaclitaxelPhase 21 trial
TAK-853Phase 1/21 trial
NiraparibN/A5 trials
Active Trials
NCT05187208Unknown102Est. Dec 2025
NCT05021562Active Not Recruiting354Est. Mar 2026
NCT04734665Unknown44Est. Mar 2024
+4 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
1
2
BIBF 1120Phase 21 trial
BIBF 1120Phase 21 trial
DoxilPhase 11 trial
Active Trials
NCT01485874Terminated11Est. Dec 2015
NCT01610869Completed117Est. Jan 2018
NCT01669798Completed32Est. Feb 2018
Pfizer
PfizerNEW YORK, NY
3 programs
1
2
Palbociclib 125mgPhase 21 trial
dalteparinPhase 21 trial
maplirpaceptPhase 1/21 trial
Active Trials
NCT05261490Terminated10Est. Feb 2024
NCT03936270Completed43Est. May 2023
NCT00239980Completed77Est. Jan 2010
CASI Pharmaceuticals
CASI PharmaceuticalsBEIJING, China
3 programs
3
ENMD-2076Phase 21 trial
MKC-1Phase 21 trial
Panzem Nanocrystal Colloidal DispersionPhase 21 trial
Active Trials
NCT01104675CompletedEst. Dec 2012
NCT00607607CompletedEst. Jan 2012
NCT00400348CompletedEst. Nov 2008
DS
Daiichi SankyoChina - Shanghai
2 programs
1
Trastzumab DeruxtecanPhase 2ADC1 trial
Digital Health Coaching ProgramN/A
Active Trials
NCT07340164Not Yet Recruiting116Est. Dec 2030
HB
HaiHe BiopharmaChina - Shanghai
2 programs
1
1
CYH33Phase 21 trial
CYH33Phase 11 trial
Active Trials
NCT04586335TerminatedEst. Feb 2023
NCT05043922Active Not RecruitingEst. Feb 2026
Astellas
2 programs
1
1
Enzalutamide 40 MGPhase 21 trial
IMAB027Phase 11 trial
Active Trials
NCT02054351Completed42Est. Oct 2015
NCT03464201Completed16Est. Nov 2020
Mereo BioPharma
Mereo BioPharmaUK - London
2 programs
1
1
NivolumabPhase 2Monoclonal Antibody1 trial
OMP-54F28, Paclitaxel and CarboplatinPhase 11 trial
Active Trials
NCT02092363CompletedEst. Dec 2017
NCT05715216Active Not RecruitingEst. Feb 2026
Xencor
XencorPASADENA, CA
2 programs
1
1
vudalimabPhase 2Monoclonal Antibody1 trial
XmAb541Phase 11 trial
Active Trials
NCT06276491RecruitingEst. Dec 2028
NCT05032040Active Not RecruitingEst. Dec 2025
Novartis
NovartisBASEL, Switzerland
2 programs
1
1
Imatinib MesylatePhase 2
[68Ga]Ga-EVS459Phase 11 trial
Active Trials
NCT06376253Terminated4Est. Jul 2025
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
1
RegorafenibPhase 2Small Molecule1 trial
SorafenibPhase 1/2Small Molecule1 trial
Active Trials
NCT00526799Terminated30Est. Aug 2010
NCT05113368Recruiting31Est. Feb 2027
Aurigene
1 program
1
AUR109 200mgPhase 21 trial
Active Trials
NCT06760702Recruiting90Est. May 2027
Knight Therapeutics
1 program
1
AbraxanePhase 21 trial
Active Trials
NCT01821859Terminated5Est. Nov 2011
US WorldMeds
1 program
1
Autologous genetically modified ADP-A2M4CD8 cellsPhase 21 trial
Active Trials
NCT05601752Active Not RecruitingEst. Aug 2026
Bristol Myers Squibb
1 program
1
CarboplatinPhase 2
HCW Biologics
1 program
1
Carboplatin AUC 5 and paclitaxelPhase 21 trial
Active Trials
NCT05145569WithdrawnEst. Jan 2028
Karyopharm Therapeutics
1 program
1
DecitabinePhase 21 trial
Active Trials
NCT05983276RecruitingEst. Aug 2031

+31 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedaNiraparib
AbbVieMirvetuximab soravtansine plus Bevacizumab
Chipscreen Bioscienceschiauranib
Zai LabZL-2306
BeOne MedicinesPamiparib capsule
RochePaclitaxel
Rocheatezolizumab + avastin + platinum-based chemotherapy
EisaiFarletuzumab
GenentechCarboplatin
Merck & Co.Carboplatin
Sutro BiopharmaLuveltamab tazevibulin
AB ScienceMasitinib
Merck & Co.Carboplatin
Daiichi SankyoTrastzumab Deruxtecan
Corcept TherapeuticsRelacorilant 150 mg once daily

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 7,950 patients across 50 trials

NCT05187208TakedaNiraparib

PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer

Start: Jan 2022Est. completion: Dec 2025102 patients
Phase 4Unknown
NCT05445778AbbVieMirvetuximab soravtansine plus Bevacizumab

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Start: Mar 2023Est. completion: May 2032520 patients
Phase 3Recruiting
NCT04921527Chipscreen Bioscienceschiauranib

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Start: Dec 2021Est. completion: Jul 2025
Phase 3Recruiting
NCT03709316Zai LabZL-2306

A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Start: Jun 2018Est. completion: Dec 2023384 patients
Phase 3Unknown
NCT03519230BeOne MedicinesPamiparib capsule

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Start: May 2018Est. completion: Jan 2027
Phase 3Active Not Recruiting
NCT03038100RochePaclitaxel

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start: Mar 2017Est. completion: Aug 20221,301 patients
Phase 3Completed
NCT02891824Rocheatezolizumab + avastin + platinum-based chemotherapy

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Start: Sep 2016Est. completion: Feb 2024614 patients
Phase 3Completed
NCT00849667EisaiFarletuzumab

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Start: Apr 2009Est. completion: Apr 20131,100 patients
Phase 3Terminated
NCT00434642GenentechCarboplatin

A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma

Start: Apr 2007Est. completion: Jul 2013484 patients
Phase 3Completed
NCT00050336Merck & Co.Carboplatin

Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)

Start: Dec 2002Est. completion: Mar 2004702 patients
Phase 3Terminated
NCT05870748Sutro BiopharmaLuveltamab tazevibulin

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Start: Jul 2023Est. completion: Aug 2025600 patients
Phase 2/3Terminated
NCT02490488AB ScienceMasitinib

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

Start: Apr 2014Est. completion: Dec 2020
Phase 2/3Completed
NCT00003880Merck & Co.Carboplatin

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

Start: Feb 1999Est. completion: Aug 2001132 patients
Phase 2/3Terminated
NCT07340164Daiichi SankyoTrastzumab Deruxtecan

Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

Start: Dec 2025Est. completion: Dec 2030116 patients
Phase 2Not Yet Recruiting
NCT06906341Corcept TherapeuticsRelacorilant 150 mg once daily

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Start: Apr 2025Est. completion: Dec 2026270 patients
Phase 2Recruiting
NCT05952453Merck & Co.Carboplatin

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

Start: Feb 2025Est. completion: Dec 203020 patients
Phase 2Recruiting
NCT06760702AurigeneAUR109 200mg

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers

Start: Nov 2024Est. completion: May 202790 patients
Phase 2Recruiting
NCT06433219Merck & Co.Tuvusertib

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Start: Oct 2024Est. completion: Jun 202663 patients
Phase 2Active Not Recruiting
NCT05145569HCW BiologicsCarboplatin AUC 5 and paclitaxel

Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer

Start: May 2024Est. completion: Jan 2028
Phase 2Withdrawn
NCT06251947Chia Tai TianQing Pharmaceutical GroupEfbemalenograstim Alfa

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Start: Apr 2024Est. completion: Dec 2026
Phase 2Recruiting
NCT05983276Karyopharm TherapeuticsDecitabine

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Start: Nov 2023Est. completion: Aug 2031
Phase 2Recruiting
NCT05601752US WorldMedsAutologous genetically modified ADP-A2M4CD8 cells

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Start: Jun 2023Est. completion: Aug 2026
Phase 2Active Not Recruiting
NCT05715216Mereo BioPharmaNivolumab

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Start: Mar 2023Est. completion: Feb 2026
Phase 2Active Not Recruiting
NCT05775289RochePaclitaxel

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Start: Mar 2023Est. completion: Jun 2026182 patients
Phase 2Active Not Recruiting
NCT05032040Xencorvudalimab

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Start: Jul 2022Est. completion: Dec 2025
Phase 2Active Not Recruiting
NCT05113368BayerRegorafenib

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Start: Jun 2022Est. completion: Feb 202731 patients
Phase 2Recruiting
NCT05043922HaiHe BiopharmaCYH33

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Start: Oct 2021Est. completion: Feb 2026
Phase 2Active Not Recruiting
NCT04734665TakedaNiraparib

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Start: Jul 2021Est. completion: Mar 202444 patients
Phase 2Unknown
NCT04417192Merck & Co.Olaparib

Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer

Start: Dec 2020Est. completion: Jun 202330 patients
Phase 2Completed
NCT04392102Zai LabZL-2306

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

Start: Aug 2020Est. completion: Aug 202215 patients
Phase 2Completed
NCT04217798Zai LabNiraparib

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

Start: May 2020Est. completion: Jun 202236 patients
Phase 2Unknown
NCT03936270PfizerPalbociclib 125mg

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

Start: Mar 2020Est. completion: May 202343 patients
Phase 2Completed
NCT05979298CureLab OncologyGemcitabine

Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

Start: Nov 2019Est. completion: Dec 202440 patients
Phase 2Unknown
NCT03901118Chipscreen Bioscienceschiauranib

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Start: Jul 2019Est. completion: Dec 2020
Phase 2Completed
NCT03430700Merck & Co.Pembrolizumab

Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer

Start: May 2019Est. completion: Mar 202528 patients
Phase 2Unknown
NCT03759587TakedaNiraparib

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Start: Dec 2018Est. completion: Dec 202219 patients
Phase 2Completed
NCT03759600TakedaNiraparib

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

Start: Dec 2018Est. completion: Dec 202220 patients
Phase 2Completed
NCT03648489TakedaPaclitaxel

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Start: Sep 2018Est. completion: Nov 2023134 patients
Phase 2Completed
NCT03470805AstraZenecaOlaparib

Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma

Start: Jun 2018Est. completion: Jul 20229 patients
Phase 2Completed
NCT03464201AstellasEnzalutamide 40 MG

Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study

Start: Apr 2018Est. completion: Nov 202016 patients
Phase 2Completed
NCT03414047Eli Lilly and CompanyPrexasertib

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Start: Apr 2018Est. completion: Oct 2020172 patients
Phase 2Completed
NCT03117933AstraZenecaOlaparib

Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Start: Mar 2017Est. completion: Dec 2023139 patients
Phase 2Completed
NCT02766582Merck & Co.Pembrolizumab

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

Start: Oct 2016Est. completion: Dec 202329 patients
Phase 2Completed
NCT01610869Boehringer IngelheimBIBF 1120

Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer

Start: Aug 2014Est. completion: Jan 2018117 patients
Phase 2Completed
NCT01991210GenentechDNIB0600A

A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

Start: Feb 2014Est. completion: Aug 201695 patients
Phase 2Terminated
NCT01556841Oxford BiomedicaTroVax®

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer

Start: Nov 2013Est. completion: Apr 201994 patients
Phase 2Completed
NCT01669798Boehringer IngelheimBIBF 1120

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Start: Feb 2013Est. completion: Feb 201832 patients
Phase 2Completed
NCT01696032Astex PharmaceuticalsSGI-110

SGI-110 in Combination With Carboplatin in Ovarian Cancer

Start: Sep 2012Est. completion: Aug 2016
Phase 2Completed
NCT01059643Eli Lilly and CompanyLY2523355

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Start: Apr 2011Est. completion: Dec 2012103 patients
Phase 2Completed
NCT01164995Merck & Co.Carboplatin

Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer

Start: Jul 2010Est. completion: Apr 202324 patients
Phase 2Completed

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
1h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
3h ago

Executive Director, I.T.- Head of Security Architecture, Engineering, and Delivery

Gilead Sciences
United States - California - Foster City
17h ago
$281K - $364K/yr

Sr Research Associate, Analytical Operations

Gilead Sciences
United States - California - Oceanside
17h ago
$86K - $112K/yr

Associate Director, Insights & Analytics Platform Technology Lead

Gilead Sciences
United States - California - Foster City
17h ago
$196K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 late-stage (Phase 3) programs — potential near-term approvals
8 actively recruiting trials targeting 7,950 patients
30 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)